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In a randomized, double-blind, controlled trial, 546 patients with complicated skin and skin structure
infections received tigecycline 100 mg/day (a 100-mg initial dose and then 50 mg intravenously twice daily) or
the combination of vancomycin 2 g/day (1 g intravenously twice daily) and aztreonam 4 g/day (2 g intravenously
twice daily) for up to 14 days. The primary end point was the clinical response in the clinical modified
intent-to-treat (c-mITT) and clinically evaluable (CE) populations at the test-of-cure visit 12 to 92 days after
the last dose. The microbiologic response at the test-of-cure visit was also assessed. Safety was assessed by
physical examination, laboratory results, and adverse event reporting. Five hundred twenty patients were
included in the c-mITT population (tigecycline group, n  261; combination group, n  259), and 436 were
clinically evaluable (tigecycline group, n  223; combination group, n  213). The clinical responses in the
tigecycline and the combination vancomycin and aztreonam groups were similar in the c-mITT population
(84.3% versus 86.9%; difference, 2.6% [95% confidence interval, 9.0, 3.8]; P  0.4755) and the CE popu-
lation (89.7% versus 94.4%; difference, 4.7% [95% confidence interval, 10.2, 0.8]; P  0.1015). Microbiologic
eradication (documented or presumed) occurred in 84.8% of the patients receiving tigecycline and 93.2% of the
patients receiving vancomycin and aztreonam (difference, 8.5 [95% confidence interval, 16.0, 1.0]; P 
0.0243). The numbers of patients reporting adverse events were similar in the two groups, with increased
nausea and vomiting rates in the tigecycline group and an increased incidence of rash and increases in alanine
aminotransferase and aspartate aminotransferase levels in the combination vancomycin and aztreonam group.
Tigecycline was shown to be safe and effective for the treatment of complicated skin and skin structure
infections.
The treatment of skin and skin structure infections (SSSIs)
with antibiotics is challenging. The disease in patients with
SSSIs has a diverse bacterial etiology, with polymicrobial cu-
taneous infections that often include gram-positive organisms,
Pseudomonas aeruginosa, and enteric gram-negative bacilli and
anaerobes (4, 8, 9, 11, 13, 33). In addition, a long-standing
concern with SSSIs in the hospital is the emergence of methi-
cillin-resistant Staphylococcus aureus (MRSA) (3). Inadequate
coverage in the treatment of SSSIs may result in the develop-
ment of antimicrobial resistance and clinical failure (9, 10, 35).
The appearance of MRSA highlights the urgent need for new
first-line therapies that are empirically effective against sus-
pected pathogens, including resistant organisms (5, 38).
Tigecycline has been approved by the U.S. Food and Drug
Administration as the first glycylcycline (36) that is indicated
for the treatment of complicated SSSIs (cSSSIs) caused by
Escherichia coli, Enterococcus faecalis (vancomycin-susceptible
isolates only), Staphylococcus aureus (methicillin-susceptible
and -resistant isolates), Streptococcus agalactiae, the Strepto-
coccus anginosus group (which includes S. anginosus, S. inter-
medius, and S. constellatus), Streptococcus pyogenes, and Bac-
teroides fragilis (40). Tigecycline exhibits a spectrum of in vitro
activity expanded beyond that of other broad-spectrum antibi-
otics because of its activity against pathogens that are suscep-
tible and resistant to other antibiotics (1, 15, 29). Tigecycline
inhibits protein synthesis and cell growth in bacteria, presum-
ably by binding to the bacterial 30S ribosomal subunit and
blocking aminoacyl-tRNA molecules from entering the A site
of the ribosome (32). Tigecycline was designed to circumvent
two common resistance mechanisms in bacteria: efflux and
ribosomal protection (6). The activity of tigecycline is unaf-
fected by the presence of extended-spectrum -lactamases,
penicillin binding protein mutations, or gyrase mutations (2,
16, 30). Tigecycline has shown potent in vitro activity against a
broad spectrum of bacteria commonly found in cSSSI infec-
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tions, which includes MRSA, methicillin-susceptible S. aureus
(MSSA), Escherichia coli, Enterococcus faecalis, Enterococcus
faecium, Bacteroides spp., Clostridium spp., Peptostreptococcus
spp., and Fusobacterium spp. (12, 14, 22, 30, 33).
In a phase 2 study, tigecycline appeared to be efficacious and
showed an acceptable safety profile in hospitalized patients
with complicated SSSIs (31). We therefore compared the
safety and efficacy of tigecycline with those of current antibac-
terial treatments for SSSIs. Vancomycin is a tricyclic glycopep-
tide antibiotic with activity against a wide variety of gram-
positive organisms (21). However, it lacks activity against
gram-negative organisms; therefore, aztreonam was added to
the comparator treatment. Aztreonam is indicated for the
treatment of serious SSSIs caused by susceptible gram-nega-
tive microorganisms, including Escherichia coli, Proteus mira-
bilis, Serratia marcescens, Enterobacter spp., P. aeruginosa, Kleb-
siella pneumoniae, and Citrobacter spp. (20). We conducted the
present trial to determine the efficacy and safety of tigecycline
monotherapy and the combination of vancomycin and aztreo-
nam (V/A) and to compare the noninferiority of tigecycline to
V/A in hospitalized patients with skin and skin structure infec-
tions.
(These results were presented in part at the 44th Inter-
science Conference on Antimicrobial Agents and Chemother-
apy, 30 October to 2 November 2004, Washington, D.C.)
MATERIALS AND METHODS
Patients. A phase 3, randomized, double-blind study was conducted with
patients with cSSSIs between November 2002 and December 2003 at 65 inves-
tigational sites worldwide (21 countries, including countries in Europe and Asia
as well as Australia and South Africa). The protocol was reviewed and approved
by the institutional review board or ethical review committee of each participat-
ing center. Before the study began written informed consent was obtained from
each patient according to the guidelines of each institution. The trial was con-
ducted in accordance with the Declaration of Helsinki and its amendments.
Eligible patients were hospitalized men and women aged 18 years or older with
cSSSIs that either involved deep soft tissue, including extensive cellulitis at least
10 cm in width or length; required surgical intervention; or was associated with
significant underlying disease (e.g., diabetes mellitus, peripheral vascular disease,
peripheral neuropathy, and lower venous insufficiency). In addition to the infec-
tion, the patient had to have at least two of the following signs and symptoms:
drainage or discharge, fever, erythema, swelling, localized warmth, pain, and/or
white blood cell count 10,000/mm3. After the original sample for culture was
obtained, the subjects could not receive more than two doses of a nonstudy
antibacterial therapy. If a patient was considered a prior antibiotic treatment
failure, a Gram stain showing a potential isolate or a sample for baseline culture
of the infected site was obtained before the study drug was administered.
Patients were excluded if they had necrotizing fasciitis, gangrene, osteomyeli-
tis, plasmapheresis, hemoperfusion, neutropenia, a severely impaired arterial
blood supply, or any condition or medication that would impair the ability to
eradicate infections. If patients had the presence of hepatic disease (aspartate
aminotransferase [AST] or alanine aminotransferase [ALT] levels more than 10
times the upper limit of normal [ULN], a bilirubin level more than 3 times the
ULN, or the presence of acute hepatic failure or acute decompensation of
chronic hepatic failure), they were excluded from the study.
Patients were also excluded if they were hypersensitive to tigecycline, vanco-
mycin, aztreonam, or tetracycline agents or had a known or suspected concom-
itant infection that required treatment with another antimicrobial agent. If a
patient had an uncomplicated SSSI (e.g., simple abscesses, folliculitis, impetigi-
nous lesions, furunculosis, or superficial cellulitis) or an SSSI that could be
treated by surgery alone, he or she was excluded from the study.
Patients meeting the inclusion and exclusion criteria were included in the
intent-to-treat (ITT) population, patients who received at least one dose of study
drug were included in the modified ITT (mITT) population, and patients in the
mITT population who had clinical evidence of a cSSSI by meeting the minimal
disease criteria were included in the clinical modified (c-mITT) population.
Procedures. We conducted the present trial to determine the noninferiority of
tigecycline to V/A in hospitalized patients with skin and skin structure infections.
The primary objective was to determine the safety and efficacy of tigecycline
compared with those of the combination of V/A for the treatment of cSSSIs in
hospitalized patients. The secondary objectives, which were exploratory in na-
ture, were to obtain additional in vitro susceptibility data on tigecycline for a
range of bacteria that cause cSSSIs and to compare its microbiological efficacy
among treatment arms in patients with cSSSIs.
Patients were randomly assigned (1:1) to receive either tigecycline with pla-
cebo or the combination of V/A intravenously (i.v.) for up to 14 days. For
patients assigned to the tigecycline group, the initial i.v. dose of 100 mg tigecy-
cline was followed by 50 mg twice a day (approximately every 12 h) in 250 ml of
normal saline infused over 60 min. Following each tigecycline infusion, patients
received 100 ml normal saline placebo infused over 60 min. For patients assigned
to the combination V/A group, 1 g vancomycin in 250 ml of normal saline was
administered i.v. over 60 min, followed by 2 g aztreonam in 100 ml of saline over
60 min, twice a day (approximately every 12 h). Aztreonam could be discontinued
after 48 h, according to the investigator’s clinical judgment.
When baseline culture results became available, the investigator reviewed the
results and assessed them for the presence of a gram-negative pathogen. The
investigator could then decide that aztreonam or placebo coverage was no longer
necessary; however, aztreonam could be continued at the investigator’s discre-
tion, even in the absence of a gram-negative pathogen. The unblinded dispenser
discontinued aztreonam or placebo infusion when the dispenser was ordered to
do so by the investigator.
Clinical and microbiologic assessments. Samples of blood were obtained, and
samples of the infection site for culture were obtained with superficial swab.
Patients in the c-mITT population were considered to be clinically evaluable
(CE) if they did not have P. aeruginosa as a sole baseline isolate, received no
concomitant antibiotic after their first dose of study medication (tigecycline or
V/A), and had an assessment of cure or failure at the test-of-cure visit. All other
patients were considered unevaluable. Patients included in the microbiologically
evaluable (ME) population were CE patients for whom one or more causative
isolates were identified from the baseline culture and classification of the micro-
biologic response (eradication [documented or presumed], persistence, or super-
infection [on-therapy emergence of a new isolate at the site of the infection with
the emergence or worsening of signs and symptoms of infection; i.e., the patient
was deemed a clinical failure]) at the test-of-cure visit could be determined. The
test-of-cure assessment took place at least 12 days but no more than 92 days after
the last dose of study.
The clinical response within the CE and c-mITT populations at the test-of-
cure visit (12 to 92 days after last dose) was the primary efficacy end point. An
investigator blinded to treatment assessed drainage and/or discharge, fever,
erythema, swelling and/or induration, pain and/or tenderness to palpation, extent
of infection (width and length), and localized warmth. Based on these assess-
ments, the investigator evaluated the subject’s clinical response to therapy (cure,
failure, or indeterminate). At the test of cure, the patients were considered by the
investigator to have a clinical cure if the patients had resolution of signs and
symptoms such that no further antibiotic therapy was required. Patients were
considered clinical failures if they had an inadequate response to therapy that
required additional antibiotic therapy at any point during the study.
Microbiologic efficacy was evaluated at both the patient level (eradication
[documented or presumed], persistence, superinfection, or indeterminate) and
the isolate level (eradication [documented or presumed], persistence, or inde-
terminate). At both the patient and the isolate levels, the documented eradica-
tion rate (the primary baseline pathogen and all baseline isolates were not
present in a repeat culture of a sample taken from the original site of infection)
and the presumed eradication rate (a clinical response of cure precluded the
availability of a specimen for culture) were determined. Skin cultures were the
principal source of the baseline isolate; however, a blood isolate could be used if
no baseline isolate was identified from the skin source. All specimens (blood
cultures and aerobic and anaerobic cultures of specimens from the primary site
of infection) were sent to local laboratories for primary identification of the
isolates and were tested for susceptibility to tigecycline by Kirby-Bauer disk
diffusion tests. The isolates recovered were subcultured and tested for suscepti-
bility at a central laboratory by using both broth microdilution tests, to determine
the MIC, and Kirby-Bauer disk diffusion tests by procedures published by the
CLSI (formerly NCCLS) (26–28). MICs for tigecycline were determined by a
reference broth microdilution method with fresh Mueller-Hinton medium. The
provisional MIC breakpoints, based on previous preclinical investigations, were
as follows: 2 g/ml for susceptible; 2 to 8 g/ml for intermediate; and 8
g/ml for resistant. The MIC50 and the MIC90 represent the concentration of
antibiotic that inhibited the growth of 50% and 90% of the isolates, respectively.
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Organisms isolated from baseline cultures were considered to be the primary
baseline isolate based on the frequency with which those organisms are identified
in the particular disease state (13, 17–19, 37).
Safety evaluation. The safety population comprised all patients who received
at least one dose of study medication, i.e., the mITT population. Safety assess-
ments included a physical examination and 12-lead electrocardiograms at the
baseline. Vital signs (temperature, heart rate, blood pressure) and clinical lab-
oratory parameters (hematology, blood chemistry evaluations, and coagulation
parameters) were assessed at the baseline, day 3, day 7, day 14 or the last day of
therapy, and the test-of-cure visit. Adverse events (AEs) and treatment-emer-
gent AEs (TEAEs), i.e., AEs that occurred or worsened during treatment, were
recorded throughout the study period. Since renal failure is a frequent compli-
cation of bacteremia in hospitalized patients (35) and the vancomycin dosage
could be adjusted according to the creatinine clearance levels for patients with
compromised renal function, as suggested by the vancomycin label (21), serum
creatinine levels were determined at the baseline, day 3, day 7, day 14, or the last
day of therapy, and at the test-of-cure visit. We had no requirement for moni-
toring of vancomycin levels.
Statistical analysis. In order to determine the noninferiority of tigecycline to
the combination of V/A for clinical and microbiologic responses, a two-sided
95% confidence interval (CI) for the true difference in efficacy (tigecycline minus
the combination of V/A) was used. The CI was corrected for continuity. Non-
inferiority was concluded if the lower limit of the two-sided 95% CI was greater
than or equal to 15 (i.e., 15%). For all the subpopulation analyses (e.g.,
subgroup analyses and analyses for monomicrobial versus polymicrobial infec-
tions), an adjusted difference between treatment groups with its 95% CI was
calculated from a generalized linear model with a binomial probability function
and an identity link. For end points involving comparisons of tigecycline and the
combination of V/A with small sample sizes, the method of Wilson (39), cor-
rected for continuity, was used. The method used to compute the two-sided 95%
CI for a single proportion was the “exact” method of Clopper and Pearson (7).
Throughout this article, “significant” refers to a P value less than 0.05. All
analyses other than that for the primary end point are considered secondary,
sensitivity, or exploratory analyses. P values for these additional analyses have
not been corrected for multiplicity and should be considered descriptive statistics
only.
RESULTS
Of the 546 patients randomly assigned, 3 did not receive any
drug, 274 received tigecycline (50.5%), and 269 (49.5%) re-
ceived the combination of V/A (Fig. 1) and were included in
the mITT population. Because 23 patients did not meet the
criteria for the severity of infection, 520 patients (tigecycline
group, n  261; combination group, n  259) were included in
the c-mITT population. Eighty-four patients of the c-mITT
population did not meet the evaluability criteria, and 436 pa-
tients (tigecycline group, n  223; V/A combination group, n 
213) were included in the CE population. No baseline and/or
susceptible isolates were found in 124 CE patients; therefore,
312 patients (tigecycline group, n  164; V/A combination
group, n  148) were included in the ME population.
Both treatment groups had similar demographic character-
istics, clinical diagnoses, causes of infection, and comorbid
conditions (Table 1). The most common diagnosis in both
treatment groups was deep soft tissue infection involving cel-
lulitis. Approximately half of the original infections were spon-
taneous, about 30% were due to traumatic injury, and 12%
resulted from surgeries. In the mITT population, fewer pa-
tients in the tigecycline group (n  13; 4.7%) than in the V/A
combination group (n  27; 10%) received concomitant anti-
biotics, administered after the start of treatment with the study
drug through the last dose of study drug (Fisher’s exact test, P
 0.021).
Approximately 80% of the mITT population in each treat-
ment group completed therapy and were included in the CE
population. In both groups, the reasons for exclusion from the
CE population were broken treatment blind (12 of 274 patients
[4.4%] and 17 of 269 patients [6.3%] in the tigecycline and the
V/A groups, respectively), failure to meet the inclusion criteria
and/or the minimal disease criteria (13 of 274 patients [4.7%]
and 11 of 269 patients [4.1%] in the tigecycline and the V/A
groups, respectively), no clinical evaluation at test of cure (10
of 274 patients [3.6%] and 8 of 269 patients [3.0%] in the
tigecycline and the V/A groups, respectively), the presence of
Pseudomonas at the baseline (1 of 274 patients [0.4%] and 3 of
269 patients [1.1%] in the tigecycline and the V/A groups,
respectively), and the receipt of more than two prior doses of
antibiotic after the sample for the baseline culture was ob-
tained (1 of 274 patients [0.4%] and 2 of 269 patients [0.7%] in
the tigecycline and the V/A groups, respectively).
The trial met the predefined statistical criteria for demon-
stration that the efficacy of the tigecycline montherapy was not
inferior to that of combination V/A therapy (Table 2). For the
CE population, the success rates were 89.7% and 94.4% (dif-
ference, 4.7 [95% CI differences, 10.2 to 0.8]) for the tige-
cycline and the V/A treatment groups, respectively. In the
c-mITT population, the cure rates were 84.3% and 86.9%
(difference, 2.6 [95% CI differences, 9.0, 3.8]) for the tige-
cycline and the V/A treatment groups, respectively. In the
secondary analyses, the results for the ME population were
generally consistent with those for the CE and the c-mITT
populations. At the test-of-cure visit, tigecycline was noninfe-
rior to V/A and thus may be as effective as the combination of
V/A in the ME and microbiologic modified ITT (m-mITT)
patients with both monomicrobial and polymicrobial infections
(Table 2).
The clinical cure rates were also equivalent in the two treat-
ment groups when they were compared across the baseline
diagnoses of infection (Table 3). Although there is little power
to determine differences between the dose groups, tigecycline
monotherapy was comparable to V/A for the subsets of pa-
tients with baseline diagnoses of diabetes, peripheral vascular
disease, or bacteremia. A small number of CE patients pre-
sented with bacteremia at the baseline (15 patients in the
tigecycline arm and 10 patients in the V/A arm). Although the
calculations are based on asymptotic properties, which may not
be verified in the case of a small sample size, no differences in
cure rates were seen between the two treatment groups in the
presence or absence of bacteremia. Similarly, no differences in
the cure rates were seen between the two treatment groups in
the few patients in the CE population with peripheral vascular
disease (10 and 12 patients in the tigecycline and the V/A
treatment groups, respectively). In the ME population, the
microbial eradication rates (documented and presumed) were
84.8% (95% CI, 78.3, 89.9) and 93.2% (95% CI, 87.9, 96.7) for
tigecycline and the combination of V/A, respectively, at the
test-of-cure visit (difference, 8.5 [95% CI differences, 16.0,
1.0]) (Table 4).
The microbiologic eradication rates (documented and pre-
sumed) at the test-of-cure visit for seven selected isolates of
clinical interest, as they are the causes of cSSSIs, were compa-
rable in the tigecycline and the V/A groups (Table 5). Among
patients infected with MRSA and MSSA, the clinical and the
microbiologic success rates were 83% and 87%, respectively,
for tigecycline-treated patients and 50% and 95%, respectively,
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for the V/A-treated patients. MIC90 values for tigecycline were
uniformly low for the most prevalent isolates, including the
MRSA and MSSA isolates, compared with those for V/A (Ta-
ble 6).
Isolates with a fourfold or greater increase in the MIC from
the baseline were evaluated for patients treated with tigecy-
cline. Two patients in the study were identified to be infected
with isolates deemed to be indeterminate or resistant to tige-
cycline, as defined by the provisional breakpoints, based on
previous preclinical investigations.
Ribotyping analysis showed that the first patient acquired a
second strain of K. pneumoniae (resistant) after the baseline
culture grew a susceptible strain. In the second patient, K.
pneumoniae grew only in a culture of a sample taken after
the baseline culture, and ribotyping analysis was not per-
formed. These results showed that neither of the strains
FIG. 1. Population analyzed.
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developed documented resistance to tigecycline during ther-
apy.
Data from all patients in the mITT population were used for
the analysis of safety. Tigecycline had a safety profile consistent
with that seen in phase 1 (23, 24, 34) and phase 2 (25, 31) trials.
Table 7 shows the frequency and distribution of TEAEs that
occurred in at least 3% of the patients. The majority of AEs
were considered unrelated to a study medication and were
mild to moderate in intensity. Nausea and vomiting were the
most commonly reported TEAEs in the tigecycline group, oc-
TABLE 1. Demographic and baseline characteristics of mITT population
Characteristic Tigecycline group (n  274) V/A group (n  269)
Age (yr) (mean [SD]) 48.8 (17.0) 50.1 (17.8)
Sex (no. [%] of patients)
Men 167 (60.9) 163 (60.6)
Women 107 (39.1) 106 (39.4)
Ethnic origin (no. [%] of patients)
White 227 (82.8) 223 (82.9)
Black 20 (7.3) 20 (7.4)
Asian 19 (6.9) 22 (8.2)
Other 8 (2.9) 4 (1.5)
Wt (kg) (mean [SD]) 82.5 (21.0) 81.5 (20.5)
Creatinine clearance (ml/min) (mean [SD]) 109.4 (42.4) 104.3 (41.2)
Chief clinical diagnosis (no. [%] of patients)
Infected ulcers 25 (9.1) 19 (7.1)
Major abscesses 73 (26.6) 84 (31.2)
Burns 9 (3.3) 8 (3.0)
Deep soft tissue infection 167 (60.9) 157 (58.4)
Cellulitis 160 (58.4) 148 (55.0)
Complicated underlying disease 26 (9.5) 26 (9.7)
10 cm (where anatomically applicable) 144 (52.6) 130 (48.3)
Requiring surgery or drainage 71 (25.9) 73 (27.1)
Wound infection 7 (2.6) 9 (3.3)
Other 0 1 (0.4)a
Cause of infection (no. [%] of patients)
Trauma 80 (29.2) 81 (30.1)
Spontaneous 144 (52.6) 132 (49.1)
Bite (human, insect, animal) 6 (2.2) 15 (5.6)
Surgery 33 (12.0) 32 (11.9)
Injection 10 (3.6) 9 (3.3)
Other 1 (0.4) 0
Comorbidity conditions (no. [%] of patients)
Diabetes mellitus 41 (15.0) 32 (11.9)
Peripheral vascular disease 21 (7.7) 19 (7.1)
a This patient had purulent drainage at peripheral i.v. catheter sites.
TABLE 2. Clinical success rates by study population at test-of-cure visit
Population
Tigecycline V/A













CE 200/223 89.7 (84.9, 93.3) 201/213 94.4 (90.4, 97.1) 4.7 (10.2, 0.8) 0.001 0.1015
c-mITT 220/261 84.3 (79.3, 88.5) 225/259 86.9 (82.1, 90.7) 2.6 (9.0, 3.8) 0.001 0.4755
ME 148/164 90.2 (84.6, 94.3) 143/148 96.6 (92.3, 98.9) 6.4 (12.4, 0.3) 0.0019 0.0372
Monomicrobial 83/90 92.2 (84.6, 96.8) 78/81 96.3 (89.6, 99.2) 4.1 (12.6, 4.6)
Polymicrobial 65/74 87.8 (78.2, 94.3) 65/67 97.0 (89.6, 99.6) 9.2 (19.6, 1.2) 6.2 (11.7, 0.7)a
m-mITT 180/204 88.2 (83.0, 92.3) 177/196 90.3 (85.3, 94.1) 2.1 (8.6, 4.5) 0.001 0.6114
Monomicrobial 104/114 91.2 (84.5, 95.7) 99/111 89.2 (81.9, 94.3) 2.0 (6.6, 10.8)
Polymicrobial 76/90 84.4 (75.3, 91.2) 78/85 91.8 (83.8, 96.6) 7.3 (17.9, 3.4) 1.7 (7.9, 4.5)a
a Adjusted difference.
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curring in 25% and 12% of patients, respectively, whereas they
occurred in 5% and 2% of patients, respectively, in the V/A
combination group. Although nausea and vomiting were usu-
ally related to tigecycline, approximately 96% of the incidents
were mild to moderate in severity (grade 1 or 2). Significantly
more tigecycline patients than patients in the V/A combination
group (P  0.001) received antiemetic therapy. The most com-
mon antiemetic treatment was metoclopramide.
Serious adverse events were reported for 28 patients during
the study: 15 patients in the tigecycline group (5.5%) and 13
patients in the V/A combination group (4.8%). The most fre-
quent SAEs in the tigecycline-treated patients were cellulitis
and infection (three patients each; 2.2% combined). The most
frequent serious adverse event among V/A combination-
treated patients was cellulitis (two patients; 0.7%).
Adverse events were the most frequent primary reason for
discontinuation of the study drug (tigecycline, n  6 [2.2%];
V/A combination, n  13 [4.8%]). Three tigecycline patients
discontinued treatment because of nausea. Seven V/A combi-
nation patients but no tigecycline patients (P  0.007) discon-
tinued treatment because of skin disorders: dermatitis allergic,
furunculosis, pruritic rash, pruritis, and rash.
There was one death during the study. A 74-year-old man
died from adenocarcinoma, but in the investigators’ opinion,
the death was not related to the study treatment. The patient
received 7 days of treatment with tigecycline and died 1 day
after the completion of therapy. Adenocarcinoma was present
at the start of the study but was not discovered until surgery
was performed.
No hematologic or serum chemistry abnormalities were as-
sociated with the use of tigecycline. In the V/A combination
group, AST and ALT liver enzyme level increases were the
most commonly reported TEAEs, occurring in 5% and 7% of
patients, respectively, whereas they occurred in 2% and 2% of
patients in the tigecycline group, respectively. Elevations in
AST and ALT levels have been reported in 1% of aztreo-
nam-treated patients (20) but are not described in the vanco-
mycin prescription information (21). Significantly more pa-
tients in the V/A combination group (13.9%) had low
lymphocyte levels compared with the number in the tigecycline
TABLE 3. Clinical success rates by exploratory subgroupsa at test-of-cure visit
Clinical diagnosis
Tigecycline V/A Difference (tigecycline  V/A)
n/Nb % (95% CI) n/N % (95% CI) % (95% CI)
Soft tissue infection 118/130 90.8 (84.4, 95.1) 108/118 91.5 (85.0, 95.9) 0.8 (8.6, 7.3)
Abscesses 58/66 87.9 (77.5, 94.6) 73/75 97.3 (90.7, 99.7) 9.5 (20.6, 0.4)
Ulcers 15/18 83.3 (58.6, 96.4) 12/12 100.0 (73.5, 100.0) 16.7 (42.3, 15.9)
Burns 9/9 100.0 (66.4, 100.0) 8/8 100.0 (63.1, 100.0) 0.0 (37.1, 40.2)
Diabetes 21/25 84.0 (63.9, 95.5) 23/27 85.2 (66.3, 95.8) 1.2 (24.4, 21.3)
Peripheral vascular
disease
7/10 70.0 (34.8, 93.3) 10/12 83.3 (51.6, 97.9) 13.3 (50.6, 25.8)
Baseline bacteremia 14/15 93.3 (68.1, 99.8) 10/10 100.0 (69.2, 100.0) 6.7 (34.0, 28.4)
a The exploratory subgroups were the baseline diagnosis of the investigator, patients with diabetes or peripheral vascular disease, or baseline bacteremia status (CE
population).
b n, number of patients with clinical success; N, total number of patients.
TABLE 4. Microbiologic response at the subject level (ME population) at test-of-cure visit
Response
Tigecycline V/A Difference (tigecycline  V/A)
n/Na % (95% CI) n/N % (95% CI) % (95% CI) Test fornoninferiority
Test for
difference
Eradication 139/164 84.8 (78.3, 89.9) 138/148 93.2 (87.9, 96.7) 8.5 (16.0, 1.0) 0.0460 0.0243
Documented 9/139 6.5 13/138 9.4
Presumed 130/139 93.5 125/138 90.6
Monomicrobial 80/90 88.9 (80.5, 94.5) 75/81 92.6 (84.6, 97.2) 3.7 (13.5, 6.4)
Polymicrobial 59/74 79.7 (68.8, 88.2) 63/67 94.0 (85.4, 98.3) 14.3 (26.3, 1.9)
Persistence 21/164 12.8 9/148 6.1
Documented 11/21 52.4 6/9 66.7
Presumed 10/21 47.6 3/9 33.3
Monomicrobial 9/90 10.0 5/81 6.2
Polymicrobial 12/74 16.2 4/67 6.0
Superinfection 4/164 2.4 1/148 0.7
Monomicrobial 1/90 1.1 1/81 1.2
Polymicrobial 3/74 4.1 0/67 0.0
a n, number of patients with microbiologic response; N, total number of patients.
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group (4.4%) (P  0.001). A higher percentage of patients in
the tigecycline group (15.4%) had a high platelet count com-
pared with the percentage of patients in the V/A combination
group (8.9%) (P  0.024). All but one patient (in the V/A
combination group) with low platelet counts entered the study
with preexisting thrombocytopenia.
DISCUSSION
The increasing rate of antibiotic resistance in patients pre-
senting with complicated SSSIs (9, 10, 35) has spurred the need
to develop new antimicrobial therapies. Tigecycline is the first
glycylcycline that is indicated for the treatment of cSSSIs
caused by a number of pathogens common in cSSSIs (40).
Tigecycline’s spectrum of in vitro activity is expanded beyond
that of other broad-spectrum antibiotics because it is active
against pathogens that are susceptible and resistant to other
antibiotics (1, 15, 29).
In this phase 3 study, the safety and efficacy of tigecycline
monotherapy for the treatment of cSSSIs were compared with
the safety and efficacy of current standard therapy, which re-
quires combination therapy, i.e., vancomycin and aztreonam,
TABLE 5. Microbiologic response at isolate level: selected baseline isolates at test-of-cure visit (ME population)
Isolate
Tigecycline V/A
n/Na % (95% CI) n/N % (95% CI)
Staphylococcus aureus (MRSA) 5/6 83.3 (35.9–99.6) 3/6 50.0 (11.8–88.2)
Documented 0/5 0.0 0/3 0.0
Presumed 5/5 100.0 3/3 100.0
Staphylococcus aureus (MSSA) 54/62 87.1 (76.1–94.3) 55/58 94.8 (85.6–98.9)
Documented 6/54 11.1 2/55 3.6
Presumed 48/54 88.9 53/55 96.4
Streptococcus pyogenes 21/22 95.5 (77.2–99.9) 16/16 100.0 (79.4–100.0)
Documented 3/21 14.3 2/16 12.5
Presumed 18/21 85.7 14/16 87.5
Streptococcus agalactiae 4/5 80.0 (28.4–99.5) 3/3 100.0 (29.2–100.0)
Documented 1/4 25.0 0/3 0.0
Presumed 3/4 75.0 3/3 100.0
Enterococcus faecalisb 3/4 75.0 (19.4–99.4) 5/5 100.0 (47.8–100.0)
Documented 1/3 33.3 2/5 40.0
Presumed 2/3 66.7 3/5 60.0
Escherichia coli 15/16 93.8 (69.8–99.8) 13/14 92.9 (66.1–99.8)
Documented 1/15 6.7 1/13 7.7
Presumed 14/15 93.3 12/13 92.3
Bacteroides fragilis 0/0 NAc (NA) 1/1 100.0 (2.5–100.0)
Documented 0/0 NA 0/1 0.0
Presumed 0/0 NA 1/1 100.0
a n, number of patients with microbiologic response; N, total number of patients.
b In this study, all E. faecalis primary isolates were non-vancomycin-resistant Enterococcus isolates.
c NA, not applicable.





























12 0.12–0.25 0.12 0.25 12 0.50–4.00 1.00 2.00 12 128.0–128.0 128.0 128.0
Staphylococcus aureus
(MSSA)
120 0.12–0.25 0.12 0.25 120 1.00–4.00 1.00 2.00 120 128.0–128.0 128.0 128.0
Streptococcus pyogenes 38 0.03–0.25 0.06 0.12 38 0.25–1.00 0.50 1.00 38 16.0–64.0 32.0 32.0
Streptococcus
agalactiae
8 0.06–0.25 NAb NA 8 0.50–1.00 NA NA 8 128.0–128.0 NA NA
Enterococcus faecalisa 9 0.12–0.25 NA NA 9 1.00–2.00 NA NA 9 128.0–128.0 NA NA
Escherichia coli 30 0.12–0.50 0.25 0.50 30 128.0–128.0 128.0 128.0 30 0.12–0.50 0.12 0.25
Bacteroides fragilis 1 0.50–0.50 NA NA 1 32.00–32.00 NA NA
a In this study, all E. faecalis primary isolates were non-vancomycin-resistant Enterococcus isolates.
b NA, MIC50 and MIC90 values are not valid if the number of isolates is less than 10.
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to provide adequate empirical coverage. Complicated SSSIs
may be caused by gram-positive and/or gram-negative bacteria,
including resistant strains (4, 8, 9, 11, 13, 33). The efficacy of
tigecycline (a 50-mg infusion every 12 h after an initial dose of
100 mg) was noninferior to that of V/A (a 1-g/2-g infusion
every 12 h), as seen in various predefined patient populations
(CE, c-mITT, ME, m-mITT populations) at the test-of-cure
visit. These results were consistent across different species of
infecting pathogens and across different types of infections.
Tigecycline demonstrated efficacy against many isolates
commonly linked to cSSSIs, including Staphylococcus aureus,
Streptococcus pyogenes, Escherichia coli, Streptococcus agalac-
tiae, and Enterococcus faecalis. MIC90 values for tigecycline
were uniformly low for the most prevalent isolates, including
MRSA and MSSA isolates (MIC90  0.25 g/ml for both
groups). There was no evidence of the development of de-
creased susceptibility to tigecycline in this study.
The overall numbers of patients reporting adverse events
were similar in the tigecycline and the V/A groups, with in-
creased nausea and vomiting rates in the tigecycline group and
increased incidence of rash and increases in ALT levels and
AST levels in the combination V/A group.
The effective coverage of tigecycline for the treatment of
cSSSIs seen in this study and in a previous phase 2 study (31)
makes tigecycline a worthy candidate for the treatment of
SSSIs requiring hospitalization. Additionally, this study com-
pared tigecycline monotherapy with combined therapy with
vancomycin and aztreonam, highlighting its expanded broad
spectrum of activity for the treatment of cSSSIs. Based on
these results and the increasing need for new antibiotics, tige-
cycline is a promising agent for the treatment of cSSSIs, espe-
cially in the setting when empirical coverage of gram-positive
and gram-negative pathogens is warranted.
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